Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
NeoMDS
- Ownership
- Private
- Development stage
- Other
01
Overview
NeoMDS is a biotechnology company focused on developing targeted therapies for hematologic malignancies, specifically myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). The company's primary research centers on the discovery and development of small molecule inhibitors that target splicing factor mutations, such as SF3B1, which are prevalent in MDS patients. By leveraging insights into the molecular drivers of blood cancers, NeoMDS aims to provide precision medicine solutions for patients with limited treatment options. The company is currently in the pre-clinical stage of development for its lead programs.
- Therapeutic areas
- OncologyHematology
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on NeoMDS.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NeoMDS.